Verena Karsten

531 total citations
19 papers, 408 citations indexed

About

Verena Karsten is a scholar working on Molecular Biology, Hematology and Public Health, Environmental and Occupational Health. According to data from OpenAlex, Verena Karsten has authored 19 papers receiving a total of 408 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Molecular Biology, 8 papers in Hematology and 6 papers in Public Health, Environmental and Occupational Health. Recurrent topics in Verena Karsten's work include Acute Myeloid Leukemia Research (8 papers), Acute Lymphoblastic Leukemia research (5 papers) and Histone Deacetylase Inhibitors Research (4 papers). Verena Karsten is often cited by papers focused on Acute Myeloid Leukemia Research (8 papers), Acute Lymphoblastic Leukemia research (5 papers) and Histone Deacetylase Inhibitors Research (4 papers). Verena Karsten collaborates with scholars based in United States, United Kingdom and Switzerland. Verena Karsten's co-authors include Keith A. Joiner, Con J. Beckers, Huilin Qi, Paul Webster, Jean‐François Dubremetz, Anita Reddy, Ann Cahill, Raymond Kuhn, Maher Albitar and Susan O’Brien and has published in prestigious journals such as Journal of Biological Chemistry, Journal of Clinical Oncology and The Journal of Cell Biology.

In The Last Decade

Verena Karsten

19 papers receiving 400 citations

Peers

Countries citing papers authored by Verena Karsten

Since Specialization

Citations

This map shows the geographic impact of Verena Karsten's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Verena Karsten with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Verena Karsten more than expected).

Fields of papers citing papers by Verena Karsten

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Verena Karsten. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Verena Karsten. The network helps show where Verena Karsten may publish in the future.

Co-authorship network of co-authors of Verena Karsten

This figure shows the co-authorship network connecting the top 25 collaborators of Verena Karsten. A scholar is included among the top collaborators of Verena Karsten based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Verena Karsten. Verena Karsten is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

19 of 19 papers shown

#	Work	Indexed citations
1	A PHASE 2, MULTI-CENTER, OPEN-LABEL TRIAL TO EVALUATE THE SAFETY, PHARMACOKINETICS, PHARMACODYNAMICS AND EXPLORATORY CLINICAL ACTIVITY OF ALN-TTRSC, AN RNAI THERAPEUTIC FOR THE TREATMENT OF PATIENTS WITH TRANSTHYRETIN CARDIAC AMYLOIDOSIS 2015 ·Journal of the American College of Cardiology ·Julian D. Gillmore, Rodney H. Falk, Mathew S. Maurer, Michael G. Hanna, Verena Karsten, Craig Penz, Tracy Zimmermann, Jared Gollob, Philip N. Hawkins	6
2	Phase I Study of Temozolomide and Laromustine (VNP40101M) in Patients With Relapsed or Refractory Leukemia 2010 ·Clinical Lymphoma Myeloma & Leukemia ·David A. Rizzieri, Samantha LoRusso, William Tse, Khuda Dad Khan, Anjali S. Advani, Joseph O. Moore, Verena Karsten, Ann Cahill, Stanton L. Gerson	9
3	msbB deletion confers acute sensitivity to CO2 in Salmonella enterica serovar Typhimurium that can be suppressed by a loss-of-function mutation in zwf 2009 ·BMC Microbiology ·Verena Karsten, Sean R. Murray, Jeremy A. Pike, (unknown), Martina Ittensohn, (unknown), K. Brooks Low, David Bermudes	14
4	Single-Agent Laromustine, A Novel Alkylating Agent, Has Significant Activity in Older Patients With Previously Untreated Poor-Risk Acute Myeloid Leukemia 2009 ·Journal of Clinical Oncology ·Gary J. Schiller, Susan O’Brien, Arnaud Pigneux, Daniel J. DeAngelo, Norbert Vey, Jonathan Kell, Scott R. Solomon, Robert K. Stuart, Verena Karsten, Ann Cahill, Maher Albitar, Francis J. Giles	58
5	A Retrospective Comparison of Matched Elderly Patients Treated with Laromustine (Cloretazine®) or Best Supportive Care or Low Dose Ara-C in the LRF AML14 Trial 2008 ·Blood ·Robert K. Hills, Susan O’Brien, Verena Karsten, Alan K. Burnett, Francis J. Giles	2
6	A Phase II study of VNP40101M in elderly patients (pts) with de novo poor risk acute myelogenous leukemia (AML) 2008 ·Journal of Clinical Oncology ·Gary J. Schiller, Daniel J. DeAngelo, Norbert Vey, Scott R. Solomon, Robert K. Stuart, Verena Karsten, Susan O’Brien, Frank Giles	3
7	Phase I Trial of VNP40101M (Cloretazine) in Children with Recurrent Brain Tumors: A Pediatric Brain Tumor Consortium Study 2008 ·Clinical Cancer Research ·Sridharan Gururangan, Christopher D. Turner, Clinton F. Stewart, (unknown), Mehmet Koçak, Tina Young Poussaint, Peter C. Phillips∥, Stewart Goldman, Roger J. Packer, Ian F. Pollack, Susan M. Blaney, Verena Karsten, Stanton L. Gerson, James M. Boyett, Henry S. Friedman, Larry E. Kun	18
8	Phase I trial of VNP40101M in children with recurrent brain tumors—A Pediatric Brain Tumor Consortium (PBTC) study 2007 ·Journal of Clinical Oncology ·Sridharan Gururangan, Christopher D. Turner, Clinton F. Stewart, Mehmet Koçak, Tina Young Poussaint, James M. Boyett, Larry E. Kun, Verena Karsten, S L Gerson, Henry S. Friedman	1
9	Effects of Initial Treatment on Survival among Elderly AML Patients: Findings from the SEER-Medicare Database. 2006 ·Blood ·Joseph Menzin, Luke Boulanger, Verena Karsten, Ann Cahill, (unknown)	12
10	Cloretazine (VNP40101M), a Novel Sulfonylhydrazine Alkylating Agent, in Patients Age 60 Years or Older With Previously Untreated Acute Myeloid Leukemia 2006 ·Journal of Clinical Oncology ·(unknown), David A. Rizzieri, Judith E. Karp, Norbert Vey, Farhad Ravandi, Stefan Faderl, Khuda Dad Khan, Gregor Verhoef, Pierre W. Wijermans, Anjali S. Advani, Gail J. Roboz, Hagop M. Kantarjian, (unknown), Augustin Ferrant, Simon Daenen, Verena Karsten, Ann Cahill, Maher Albitar, Ghulam Mufti, Susan O’Brien	64
11	A Phase I Study of Cloretazine® and Temozolomide in Patients with Hematologic Malignancies. 2006 ·Blood ·David A. Rizzieri, William Ka Fai Tse, Khuda Dad Khan, Anjali S. Advani, (unknown), Verena Karsten, Robert B. Geller, Stanton L. Gerson	1
12	Phase I Study of Cloretazine (VNP40101M), a Novel Sulfonylhydrazine Alkylating Agent, Combined with Cytarabine in Patients with Refractory Leukemia 2005 ·Clinical Cancer Research ·Francis J. Giles, Srđan Verstovšek, Deborah A. Thomas, Stanton L. Gerson, Jörge E. Cortes, Stefan Faderl, Alessandra Ferrajoli, Farhad Ravandi, Steven M. Kornblau, Guillermo Garcia‐Manero, Elias Jabbour, Susan O’Brien, Verena Karsten, Ann Cahill, Karen Yee, Maher Albitar, Mario Sznol, Hagop M. Kantarjian	28
13	Analysis of pre-treatment O⁶-alkylguanine transferase (AGT) levels in patients (pts) with hematologic malignancies receiving VNP40101M (101M) 2005 ·Journal of Clinical Oncology ·S L Gerson, S. O’Brien, (unknown), Verena Karsten, Judith E. Karp, (unknown), G. Verhoef, Simon Daenen, Mario Sznol, F. Giles	3
14	Transmembrane Domain Modulates Sorting of Membrane Proteins in Toxoplasma gondii 2004 ·Journal of Biological Chemistry ·Verena Karsten, Ramanujan S. Hegde, Anthony P. Sinai, Mei Yang, Keith A. Joiner	28
15	A Phase I trial of the sulfonylhydrazine alkylator, VNP40101M (101M), administered weekly in patients (pts) with metastatic cancer 2004 ·Journal of Clinical Oncology ·John R. Murren, S L Gerson, Shivaani Kummar, Marianne Davies, (unknown), Edward Chu, Verena Karsten, Mario Sznol	1
16	A Phase I trial of the sulfonylhydrazine alkylator, VNP40101M (101M), administered weekly in patients (pts) with metastatic cancer 2004 ·Journal of Clinical Oncology ·John R. Murren, (unknown), Shivaani Kummar, Matthew Davies, S. C. Remick, Edward Chu, Verena Karsten, Mario Sznol	1
17	The Protozoan Parasite Toxoplasma gondii Targets Proteins to Dense Granules and the Vacuolar Space Using Both Conserved and Unusual Mechanisms 1998 ·The Journal of Cell Biology ·Verena Karsten, Huilin Qi, Con J. Beckers, Anita Reddy, Jean‐François Dubremetz, Paul Webster, Keith A. Joiner	102
18	Targeting the Secretory Pathway ofToxoplasma gondii 1997 ·Methods ·Verena Karsten, Huilin Qi, Con J. Beckers, Keith A. Joiner	21
19	Trypanosoma cruzi in Wild Raccoons and Opossums in North Carolina 1992 ·Journal of Parasitology ·Verena Karsten, (unknown), Raymond Kuhn	36

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact